Feature article - The great pharma supply chain realignment
Submitted by:
Andrew Warmington
Alex Del Priore, senior vice-president of manufacturing services at Syngene, looks at the role India might play in a changing landscape
Halozyme abandons Evotec bid
Submitted by:
Andrew Warmington
San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after a week after the latter declined to engage with it.
Three invest further into ADCs
Submitted by:
Andrew Warmington
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
New owner for Envigo
Submitted by:
Andrew Warmington
Inotiv, a US CRO specialising in nonclinical and analytical drug discovery and development services, has reached an agreement to acquire research models and services Envigo.
AlzChem completes nitrile expansion
Submitted by:
Andrew Warmington
AlzChem, the only supplier of speciality nitriles outside China, has completed a €12 million expansion that took 15 months and will increase capacity by 50%.
Merck announces ADC/HPAPI expansion
Submitted by:
Andrew Warmington
Merck KGaA is to spend €59 million to expand HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin.
A CDMO’s insight into the M&A landscape
Submitted by:
Andrew Warmington
Mark Quick, EVP of corporate development at Recipharm, discusses the M&A trend within the CDMO industry